The Indian government has proposed a major change to pharmaceutical regulations that could allow drug regulators to immediately suspend manufacturing licences for medicines that fail specified critical quality tests. The proposal, announced by the Union Ministry of Health and Family Welfare on November 4, 2026, seeks to reduce delays in regulatory action against medicines classified as Not of Standard Quality (NSQ).
Under the proposed amendments to the Drugs Rules, 1945, manufacturing licences could be suspended as soon as a Government Analyst’s report identifies failures involving active ingredient content, dissolution, related substances, impurities or sterility. The suspension would remain in place until manufacturers complete a root-cause investigation and implement corrective and preventive measures verified by regulators. The changes are still at the draft stage and have been opened for public consultation.
India Proposes Immediate Suspension of Drug Manufacturing Licences
The Health Ministry has proposed inserting new provisions into the Drugs Rules, 1945, to enable central and state licensing authorities to take immediate action when a government laboratory identifies specified critical quality failures.
Under the existing framework, regulators generally follow a prescribed procedure, including issuing a show-cause notice, before suspending or cancelling a manufacturing licence. The government believes this process can create a time gap between a medicine being declared NSQ and the beginning of regulatory action.
During that period, potentially substandard medicines could remain in circulation, increasing risks to patients and making product recalls more difficult.
The proposed amendment would allow the Central Licensing Approving Authority or the relevant State Licensing Authority to immediately suspend the manufacturing licence for the concerned drug after receiving an adverse Government Analyst report.
Importantly, the proposal is focused on the licence associated with manufacturing the affected medicine. It should not automatically be interpreted as a blanket suspension of every product or the entire business of a pharmaceutical company.
Five Critical Quality Parameters Covered by the Proposal
The proposed rules identify five quality parameters that could trigger immediate licence suspension.
| Quality parameter | What it measures | Why it matters |
|---|---|---|
| Assay | Amount of active pharmaceutical ingredient in a medicine | Ensures the medicine contains the prescribed quantity of the active ingredient |
| Dissolution | How quickly the drug releases its active ingredient | Influences how the medicine becomes available for absorption |
| Related substances | Other chemical substances associated with the drug | Helps identify unwanted substances and degradation products |
| Impurities | Unwanted chemical or other contaminants | Helps establish medicine purity and safety |
| Sterility | Whether a product meets required standards for freedom from viable microorganisms | Particularly important for sterile medicines such as injections |
These tests are important because a medicine can look normal and still fail to meet essential quality requirements.
For example, a tablet containing less active ingredient than prescribed may not deliver the intended therapeutic effect. A medicine that fails dissolution testing may not release its active ingredient properly, while sterility failures can create serious risks for patients receiving injectable products.
The proposed framework is intended to ensure that serious quality failures result in faster regulatory intervention.
Manufacturers Must Complete Root-Cause Analysis Before Licence Restoration
The proposed rules also introduce stricter conditions for restoring suspended manufacturing licences.
A company would not be able to resume manufacturing the affected drug simply by responding to a regulatory notice. It would first have to identify why the quality failure occurred and implement corrective and preventive action, commonly known as CAPA.
The process would involve two major steps:
1. Root-cause analysis: The manufacturer must investigate the underlying reason for the failure. This could involve problems with raw materials, production processes, equipment, contamination controls, testing procedures or quality-management systems.
2. Corrective and preventive action: The manufacturer must correct the identified problem and introduce measures to prevent similar failures from occurring again.
The relevant licensing authority would have to verify the implementation of these measures before revoking the suspension.
This approach is designed to prevent manufacturers from restarting production without addressing the underlying reasons for a failed quality test.
Government Proposes Faster Reporting Between Regulators
Alongside immediate suspension provisions, the government has proposed changes to Form 13, which relates to test reports issued by Government Analysts.
Under the proposed reporting mechanism, laboratory findings would be communicated to:
- The Drugs Controller General of India (DCGI).
- The relevant State or Union Territory licensing authority.
- The manufacturer of the concerned medicine.
- The marketer identified on the product label.
The central licensing authority would also be able to seek details of the manufacturer’s investigation, root-cause analysis, corrective and preventive measures, and the final action taken by the relevant state regulator.
The objective is to improve coordination between central and state authorities and reduce delays in sharing information about medicines that fail quality tests.
This is particularly important because pharmaceutical manufacturing and distribution involve multiple companies, facilities and regulatory jurisdictions.
Why India Wants Stricter Pharmaceutical Quality Controls
India is one of the world’s largest producers and exporters of generic medicines. Its pharmaceutical industry supplies affordable medicines to domestic consumers as well as healthcare markets across Asia, Africa, Europe and other regions.
However, quality failures have repeatedly brought the country’s drug manufacturing standards under scrutiny.
The issue received international attention after contaminated cough syrups manufactured in India were linked to the deaths of children in countries including The Gambia and Uzbekistan during 2022 and 2023. More recently, contaminated cough syrups were linked to child deaths in Rajasthan and Madhya Pradesh.
These incidents have increased pressure on regulators to strengthen manufacturing oversight, laboratory testing and accountability across the pharmaceutical supply chain.
The Central Drugs Standard Control Organisation (CDSCO) regularly publishes alerts identifying medicine samples that have failed prescribed quality standards. Such alerts cover different products and manufacturers and do not necessarily mean that every product made by an affected company is defective.
The proposed amendments seek to make regulatory action faster when failures involve the specified critical parameters.
What the Proposal Means for Pharmaceutical Companies
If implemented, the changes could increase compliance requirements for drug manufacturers operating in India.
Companies may need to strengthen their quality-control systems, raw-material testing, manufacturing documentation, contamination controls and internal investigation procedures.
The impact could be particularly significant for manufacturers operating multiple production facilities or supplying medicines to several markets. A serious quality failure could lead to an immediate interruption in manufacturing of the affected drug while investigations and corrective measures are completed.
The proposal could also increase the importance of quality assurance among contract manufacturers and companies that market medicines produced by third parties.
For pharmaceutical businesses, maintaining consistent manufacturing standards may become even more important than responding to regulatory action after a failed laboratory test.
At the same time, the rules will need to be implemented with reliable testing, clear communication and appropriate regulatory verification to ensure that enforcement is consistent.
Public Consultation and Implementation Timeline
The draft amendments were published on November 4, 2026, following discussions at the 65th meeting of the Drugs Consultative Committee on December 20, 2024, and recommendations from the 92nd meeting of the Drugs Technical Advisory Board on April 24, 2025.
The government has invited objections and suggestions from stakeholders and members of the public within 30 days of the relevant Gazette notification becoming available.
The amendments will take effect only after their final publication in the Official Gazette. Until then, the proposed immediate suspension mechanism should not be treated as an already implemented nationwide rule.
The Bigger Picture
India’s pharmaceutical industry has built a major global position through affordable generic medicines and large-scale manufacturing. Maintaining that position depends not only on production capacity and competitive pricing but also on the reliability and quality of medicines supplied to patients.
The proposed immediate suspension mechanism represents an effort to close the gap between identifying a serious quality failure and taking regulatory action. It also places greater responsibility on manufacturers to investigate problems and demonstrate that corrective measures have worked.
The effectiveness of the proposal will ultimately depend on laboratory capabilities, regulatory coordination, consistent enforcement and the ability of manufacturers to maintain high-quality production standards.
Looking Ahead
The next step is the completion of the 30-day public consultation process, after which the Health Ministry can consider stakeholder feedback and decide on the final amendments. Pharmaceutical companies, industry associations and regulatory experts are likely to examine how the proposed suspension mechanism will operate in practice.
If the changes are finalised, manufacturers could face faster restrictions when their medicines fail critical quality tests. For patients, the intended benefit is stronger protection against substandard medicines, while for the pharmaceutical industry, the proposal signals a greater emphasis on quality assurance, accountability and regulatory compliance.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
